PharmaResearch, the South Korean regenerative medicine company behind the blockbuster PN-based skin booster Rejuran, is accelerating its transformation into a total aesthetic enterprise. With a strong domestic medical aesthetic foothold, the company is expanding into cosmetics, beauty devices, and overseas markets, signaling new sourcing opportunities for international distributors and clinic buyers.
Market signal
PharmaResearch’s Rejuran, built on its proprietary DNA Optimizing Technology (DOT), has become a leading PN-based skin booster in Korea’s medical aesthetic market. Over a decade of clinical evidence and practitioner experience underpin its credibility. As the skin booster segment grows rapidly amid rising consumer interest in skin improvement and recovery, competition is intensifying—with filler and botulinum toxin players also entering the aesthetic space. Safety, efficacy, clinical data, and clinician trust remain key purchase criteria.
Business expansion and financial performance
PharmaResearch’s cosmetics arm, Rejuran Cosmetic, posted Q1 2026 revenue of KRW 42.2 billion (USD ~32 million), up 51% year-on-year, now accounting for 29% of total sales. The company’s consolidated Q1 revenue reached KRW 146.1 billion (USD ~112 million), with operating profit of KRW 57.3 billion (USD ~44 million)—both record highs for a quarter. Medical device revenue grew 14.5% to KRW 79.5 billion (USD ~61 million). This diversification from medical devices into cosmetics reflects the brand’s successful extension from clinic to consumer.
Global channel and market moves
Rejuran Cosmetic has expanded overseas via Amazon and TikTok in the U.S., and entered Sephora online and offline. In China, it secured Sephora placement to boost premium beauty channel exposure. Southeast Asia growth is driven by online channels. Europe is the next target, where interest in PN-based injectables is rising. PharmaResearch aims to leverage Rejuran’s brand trust and product portfolio to build a foothold among European clinicians and consumers.
New product pipeline
PharmaResearch plans to launch a microneedle radiofrequency aesthetic device within the year, expected to synergize with Rejuran. In 2025, it will introduce a recombinant collagen skin booster to strengthen its skin regeneration lineup. These additions signal a broadening portfolio for buyers seeking innovative, clinically-backed aesthetic solutions.
What buyers should watch
For overseas importers and clinic buyers, PharmaResearch’s expanding device and injectable pipeline, combined with its proven PN technology and growing cosmetics distribution, offers multiple entry points. The company’s focus on Europe and existing U.S. and China channels suggests a strategic push for global partnerships. Buyers should monitor regulatory approvals and distribution terms for new products, particularly the microneedle RF device and recombinant collagen booster.
Source: Read the original report | Published: June 01, 2026